Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study

Next Previous
X
Search
Trial Profile

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary)
  • Indications Tinnitus
  • Focus Adverse reactions
  • Acronyms AMPACT2
  • Sponsors Altamira Therapeutics; Auris Medical

    • Most Recent Events

    • 24 Apr 2017 Recruitment for AMPACT2 has been completed and the open-label extension is not being offered to patients currently enrolling in the extended TACTT3 trial, as reported in an Auris Medical media release.
    • 24 Apr 2017 This trial has been conducted at the request of the US Food and Drug Administration (FDA) to generate safety data from chronic intermittent use of Keyzilen for up to 12 months, as reported in an Auris Medical media release.
    • 24 Apr 2017 Results published in the Auris Medical Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top